Rituximab versus active surveillance in patients with follicular lymphoma

Eva Kimby¹

Affiliations

Comment

Eva Kimby. Lancet Haematol. 2025 May.

. 2025 May;12(5):e320-e321.

doi: 10.1016/S2352-3026(25)00105-X.

Eva Kimby¹

¹ Karolinska Institutet, S-14183 Huddinge, Sweden. Electronic address: eva@kimby.se.

No abstract available

Comment on

Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.
Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L, Qian W, Rana Z, Martin TL, Townsend W, Young M, Miall F, Cunningham D, Walewski J, Ferhanoglu B, Linton K, Johnston A, Seymour JF, Linch DC, Ardeshna KM. Northend M, et al. Lancet Haematol. 2025 May;12(5):e335-e345. doi: 10.1016/S2352-3026(25)00034-1. Lancet Haematol. 2025. PMID: 40306831 Clinical Trial.